aluates Reports

$ 0.0

Automative

Global Recombinant Human Coagulation VIIa Market Research Report 2026

Published Date: 2026-03-30

Report Code: QYRE-Auto-1C11632

Global Recombinant Human Coagulation VIIa Market Research Report 2022

BUY CHAPTERS

Global Recombinant Human Coagulation VIIa Market Research Report 2026

Code: QYRE-Auto-1C11632

Report

2026-03-30

Pages:101

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Novo Nordisk

LFB SA HEMA Biologics

AryoGen Pharmed

Generium

Recombinant Human Coagulation VIIa Market Size

The global Recombinant Human Coagulation VIIa market was valued at US$ 1293 million in 2025 and is anticipated to reach US$ 1661 million by 2032, at a CAGR of 3.7% from 2026 to 2032.

Recombinant Human Coagulation VIIa Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Recombinant Human Coagulation VIIa competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Recombinant activated factor VII (rFVIIa) binds to exposed tissue factor at the place of tissue and vascular injury. Thrombin generated by this process activates platelets and the coagulation cascade.

Coagulation Factor VIIa, recombinant is a coagulation factor indicated for:

Treatment of bleeding episodes and perioperative management in adults and children with Hemophilia or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann’s thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets

Treatment of bleeding episodes and perioperative management in adults with acquired haemophilia.

Drivers of the Recombinant Human Coagulation Factor VIIa (rFVIIa) Market:

Rising Prevalence of Hemophilia and Bleeding Disorders: Recombinant Factor VIIa is primarily used in treating hemophilia, especially in patients with inhibitors to Factor VIII or IX. The growing global incidence of hemophilia and other bleeding disorders is a major driver of market demand.

Advancements in Recombinant Technology: Ongoing improvements in biotechnology have led to the development of safer and more effective recombinant coagulation products. These advancements reduce the risk of bloodborne pathogen transmission, increasing their adoption over plasma-derived alternatives.

Increased Use in Trauma and Surgery: Recombinant Factor VIIa is also used in managing severe bleeding during trauma and surgical procedures, further expanding its clinical applications and boosting demand, particularly in emergency care settings.

Rising Adoption in Off-Label Uses: While its primary indication is for hemophilia, rFVIIa is increasingly being used off-label to manage uncontrolled bleeding in non-hemophiliac patients, particularly in critical care and trauma settings. This broadens its potential market.

Favorable Reimbursement Policies in Developed Regions: In regions like North America and Europe, the availability of comprehensive insurance and reimbursement for advanced therapies like rFVIIa makes these treatments more accessible to patients, supporting market growth.

Challenges of the Recombinant Human Coagulation Factor VIIa (rFVIIa) Market:

High Cost of Treatment: Recombinant Factor VIIa therapy is expensive, which can limit access, especially in low-income countries and regions without robust healthcare funding or insurance coverage.

Potential for Off-Label Use Concerns: Despite its increasing use in off-label applications, concerns about the safety and efficacy of rFVIIa in non-hemophilia patients have led to caution in its broader application. Regulatory scrutiny on off-label use may impact market expansion.

Limited Awareness and Access in Developing Regions: In many developing countries, awareness of recombinant therapies for hemophilia is limited, and access to advanced treatments is constrained by inadequate healthcare infrastructure and funding.

Competition from Alternative Therapies: Emerging gene therapies, extended half-life clotting factors, and other innovative treatments for hemophilia may compete with or reduce the demand for rFVIIa in the future. These newer therapies promise more long-term efficacy or convenience.

Regulatory Challenges: The stringent regulatory approval process for biologics, along with the ongoing need for post-market surveillance, can slow down the introduction of new products or indications, impacting the pace of market growth.

The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%. The largest manufacturer is Novo Nordisk, with a market share of more than 95%. North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%.

This report delivers a comprehensive overview of the global Recombinant Human Coagulation VIIa market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Recombinant Human Coagulation VIIa. The Recombinant Human Coagulation VIIa market size, estimates, and forecasts are provided in terms of sales volume (K Units) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Recombinant Human Coagulation VIIa market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Recombinant Human Coagulation VIIa manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Recombinant Human Coagulation VIIa Market Report

Report Metric	Details
Report Name	Recombinant Human Coagulation VIIa Market
Accounted market size in 2025	US$ 1293 million
Forecasted market size in 2032	US$ 1661 million
CAGR	3.7%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Type	Prefilled Syringe Vial
by Application	Congenital Hemophilia Acquired Hemophilia Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Novo Nordisk, LFB SA HEMA Biologics, AryoGen Pharmed, GENERIUM
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Type, by Application, , etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Provides a detailed analysis of the competitive landscape for Recombinant Human Coagulation VIIa manufacturers, covering pricing, sales and revenue shares, latest development plans, and mergers and acquisitions.
Chapter 3: Examines Recombinant Human Coagulation VIIa sales and revenue at the regional and country levels. It quantifies market size and growth potential for each region and its key countries, and outlines market development, outlook, addressable space, and national market size.
Chapter 4: Analyzes segments by Type, detailing the size and growth potential of each segment to help readers identify “blue ocean” opportunities.
Chapter 5: Analyzes market segments by Application, covering the size and growth potential of each segment to help readers identify “blue ocean” opportunities in downstream markets.
Chapter 6: Profiles key players, presenting core information on leading companies, including product sales, revenue, pricing, gross margin, product portfolio/introductions, and recent developments.
Chapter 7: Reviews the industry value chain, including upstream and downstream segments.
Chapter 8: Discusses market dynamics and recent developments, including drivers, restraints, challenges and risks for manufacturers, U.S. Tariffs and relevant policy analysis.
Chapter 9: Summarizes the key findings and conclusions of the report.

FAQ for this report

How fast is Recombinant Human Coagulation VIIa Market growing?

Ans: The Recombinant Human Coagulation VIIa Market witnessing a CAGR of 3.7% during the forecast period 2026-2032.

What is the Recombinant Human Coagulation VIIa Market size in 2032?

Ans: The Recombinant Human Coagulation VIIa Market size in 2032 will be US$ 1661 million.

What is the market share of major companies in Recombinant Human Coagulation VIIa Market?

Ans: The top three manufacturers of recombinant human coagulation VIIa in the world include Novo Nordisk, LFB SA HEMA Biologics, and GENERIUM, with a total market share of more than 99%.

What is the Novo Nordisk share in Recombinant Human Coagulation VIIa Market?

Ans: The largest manufacturer is Novo Nordisk, with a market share of more than 95%.

What is the Recombinant Human Coagulation VIIa Market share by region?

Ans: North America is the global most important consumer market for recombinant human coagulation VIIa, with a market share of about 45%.

Who are the main players in the Recombinant Human Coagulation VIIa Market report?

Ans: The main players in the Recombinant Human Coagulation VIIa Market are Novo Nordisk, LFB SA HEMA Biologics, AryoGen Pharmed, GENERIUM

What are the Application segmentation covered in the Recombinant Human Coagulation VIIa Market report?

Ans: The Applications covered in the Recombinant Human Coagulation VIIa Market report are Congenital Hemophilia, Acquired Hemophilia, Others

What are the Type segmentation covered in the Recombinant Human Coagulation VIIa Market report?

Ans: The Types covered in the Recombinant Human Coagulation VIIa Market report are Prefilled Syringe, Vial

1 Recombinant Human Coagulation VIIa Market Overview

1.1 Product Definition

1.2 Recombinant Human Coagulation VIIa by Type

1.2.1 Global Recombinant Human Coagulation VIIa Market Value by Type: 2025 vs 2032

1.2.2 Prefilled Syringe

1.2.3 Vial

1.3 Recombinant Human Coagulation VIIa by Application

1.3.1 Global Recombinant Human Coagulation VIIa Market Value by Application: 2025 vs 2032

1.3.2 Congenital Hemophilia

1.3.3 Acquired Hemophilia

1.3.4 Others

1.4 Global Recombinant Human Coagulation VIIa Market Size Estimates and Forecasts

1.4.1 Global Recombinant Human Coagulation VIIa Revenue 2021–2032

1.4.2 Global Recombinant Human Coagulation VIIa Sales 2021–2032

1.4.3 Global Recombinant Human Coagulation VIIa Market Average Price (2021–2032)

1.5 Assumptions and Limitations

2 Recombinant Human Coagulation VIIa Market Competition by Manufacturers

2.1 Global Recombinant Human Coagulation VIIa Sales Market Share by Manufacturers (2021–2026)

2.2 Global Recombinant Human Coagulation VIIa Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Recombinant Human Coagulation VIIa Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Recombinant Human Coagulation VIIa, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Recombinant Human Coagulation VIIa, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Recombinant Human Coagulation VIIa, Product Types and Applications

2.7 Global Key Manufacturers of Recombinant Human Coagulation VIIa, Date of Entry into the Industry

2.8 Global Recombinant Human Coagulation VIIa Market Competitive Situation and Trends

2.8.1 Global Recombinant Human Coagulation VIIa Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Recombinant Human Coagulation VIIa Players Market Share by Revenue

2.8.3 Global Recombinant Human Coagulation VIIa Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Recombinant Human Coagulation VIIa Market Scenario by Region

3.1 Global Recombinant Human Coagulation VIIa Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Recombinant Human Coagulation VIIa Sales by Region: 2021–2032

3.2.1 Global Recombinant Human Coagulation VIIa Sales by Region: 2021–2026

3.2.2 Global Recombinant Human Coagulation VIIa Sales by Region: 2027–2032

3.3 Global Recombinant Human Coagulation VIIa Revenue by Region: 2021–2032

3.3.1 Global Recombinant Human Coagulation VIIa Revenue by Region: 2021–2026

3.3.2 Global Recombinant Human Coagulation VIIa Revenue by Region: 2027–2032

3.4 North America Recombinant Human Coagulation VIIa Market Facts & Figures by Country

3.4.1 North America Recombinant Human Coagulation VIIa Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Recombinant Human Coagulation VIIa Sales by Country (2021–2032)

3.4.3 North America Recombinant Human Coagulation VIIa Revenue by Country (2021–2032)

3.4.4 United States

3.4.5 Canada

3.5 Europe Recombinant Human Coagulation VIIa Market Facts & Figures by Country

3.5.1 Europe Recombinant Human Coagulation VIIa Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Recombinant Human Coagulation VIIa Sales by Country (2021–2032)

3.5.3 Europe Recombinant Human Coagulation VIIa Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Recombinant Human Coagulation VIIa Market Facts & Figures by Region

3.6.1 Asia Pacific Recombinant Human Coagulation VIIa Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Recombinant Human Coagulation VIIa Sales by Region (2021–2032)

3.6.3 Asia Pacific Recombinant Human Coagulation VIIa Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Recombinant Human Coagulation VIIa Market Facts & Figures by Country

3.7.1 Latin America Recombinant Human Coagulation VIIa Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Recombinant Human Coagulation VIIa Sales by Country (2021–2032)

3.7.3 Latin America Recombinant Human Coagulation VIIa Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Recombinant Human Coagulation VIIa Market Facts & Figures by Country

3.8.1 Middle East and Africa Recombinant Human Coagulation VIIa Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Recombinant Human Coagulation VIIa Sales by Country (2021–2032)

3.8.3 Middle East and Africa Recombinant Human Coagulation VIIa Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Recombinant Human Coagulation VIIa Sales by Type (2021–2032)

4.1.1 Global Recombinant Human Coagulation VIIa Sales by Type (2021–2026)

4.1.2 Global Recombinant Human Coagulation VIIa Sales by Type (2027–2032)

4.1.3 Global Recombinant Human Coagulation VIIa Sales Market Share by Type (2021–2032)

4.2 Global Recombinant Human Coagulation VIIa Revenue by Type (2021–2032)

4.2.1 Global Recombinant Human Coagulation VIIa Revenue by Type (2021–2026)

4.2.2 Global Recombinant Human Coagulation VIIa Revenue by Type (2027–2032)

4.2.3 Global Recombinant Human Coagulation VIIa Revenue Market Share by Type (2021–2032)

4.3 Global Recombinant Human Coagulation VIIa Price by Type (2021–2032)

5 Segment by Application

5.1 Global Recombinant Human Coagulation VIIa Sales by Application (2021–2032)

5.1.1 Global Recombinant Human Coagulation VIIa Sales by Application (2021–2026)

5.1.2 Global Recombinant Human Coagulation VIIa Sales by Application (2027–2032)

5.1.3 Global Recombinant Human Coagulation VIIa Sales Market Share by Application (2021–2032)

5.2 Global Recombinant Human Coagulation VIIa Revenue by Application (2021–2032)

5.2.1 Global Recombinant Human Coagulation VIIa Revenue by Application (2021–2026)

5.2.2 Global Recombinant Human Coagulation VIIa Revenue by Application (2027–2032)

5.2.3 Global Recombinant Human Coagulation VIIa Revenue Market Share by Application (2021–2032)

5.3 Global Recombinant Human Coagulation VIIa Price by Application (2021–2032)

6 Key Companies Profiled

6.1 Novo Nordisk

6.1.1 Novo Nordisk Company Information

6.1.2 Novo Nordisk Description and Business Overview

6.1.3 Novo Nordisk Recombinant Human Coagulation VIIa Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Novo Nordisk Recombinant Human Coagulation VIIa Product Portfolio

6.1.5 Novo Nordisk Recent Developments/Updates

6.2 LFB SA HEMA Biologics

6.2.1 LFB SA HEMA Biologics Company Information

6.2.2 LFB SA HEMA Biologics Description and Business Overview

6.2.3 LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Product Portfolio

6.2.5 LFB SA HEMA Biologics Recent Developments/Updates

6.3 AryoGen Pharmed

6.3.1 AryoGen Pharmed Company Information

6.3.2 AryoGen Pharmed Description and Business Overview

6.3.3 AryoGen Pharmed Recombinant Human Coagulation VIIa Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 AryoGen Pharmed Recombinant Human Coagulation VIIa Product Portfolio

6.3.5 AryoGen Pharmed Recent Developments/Updates

6.4 GENERIUM

6.4.1 GENERIUM Company Information

6.4.2 GENERIUM Description and Business Overview

6.4.3 GENERIUM Recombinant Human Coagulation VIIa Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 GENERIUM Recombinant Human Coagulation VIIa Product Portfolio

6.4.5 GENERIUM Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Recombinant Human Coagulation VIIa Industry Chain Analysis

7.2 Recombinant Human Coagulation VIIa Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Recombinant Human Coagulation VIIa Production Mode & Process Analysis

7.4 Recombinant Human Coagulation VIIa Sales and Marketing

7.4.1 Recombinant Human Coagulation VIIa Sales Channels

7.4.2 Recombinant Human Coagulation VIIa Distributors

7.5 Recombinant Human Coagulation VIIa Customer Analysis

8 Recombinant Human Coagulation VIIa Market Dynamics

8.1 Recombinant Human Coagulation VIIa Industry Trends

8.2 Recombinant Human Coagulation VIIa Market Drivers

8.3 Recombinant Human Coagulation VIIa Market Challenges

8.4 Recombinant Human Coagulation VIIa Market Restraints

8.5 Impact of U.S. Tariffs

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Novo Nordisk

LFB SA HEMA Biologics

AryoGen Pharmed

Generium

List of Tables

Table 1. Global Recombinant Human Coagulation VIIa Market Value by Type (US$ Million), 2025 vs 2032

Table 2. Global Recombinant Human Coagulation VIIa Market Value by Application (US$ Million), 2025 vs 2032

Table 3. Global Recombinant Human Coagulation VIIa Market Competitive Situation by Manufacturers in 2025

Table 4. Global Recombinant Human Coagulation VIIa Sales (K Units) of Key Manufacturers (2021–2026)

Table 5. Global Recombinant Human Coagulation VIIa Sales Market Share by Manufacturers (2021–2026)

Table 6. Global Recombinant Human Coagulation VIIa Revenue (US$ Million) by Manufacturers (2021–2026)

Table 7. Global Recombinant Human Coagulation VIIa Revenue Share by Manufacturers (2021–2026)

Table 8. Global Market Recombinant Human Coagulation VIIa Average Price (US$/Unit) of Key Manufacturers (2021–2026)

Table 9. Global Key Players of Recombinant Human Coagulation VIIa, Industry Ranking, 2023 vs 2024 vs 2025

Table 10. Global Key Manufacturers of Recombinant Human Coagulation VIIa, Manufacturing Sites and Headquarters

Table 11. Global Key Manufacturers of Recombinant Human Coagulation VIIa, Product Types and Applications

Table 12. Global Key Manufacturers of Recombinant Human Coagulation VIIa, Date of Entry into the Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Recombinant Human Coagulation VIIa Companies by Tier (Tier 1, Tier 2, Tier 3), based on Recombinant Human Coagulation VIIa Revenue, 2025

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Recombinant Human Coagulation VIIa Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 17. Global Recombinant Human Coagulation VIIa Sales by Region (K Units), 2021–2026

Table 18. Global Recombinant Human Coagulation VIIa Sales Market Share by Region (2021–2026)

Table 19. Global Recombinant Human Coagulation VIIa Sales by Region (K Units), 2027–2032

Table 20. Global Recombinant Human Coagulation VIIa Sales Market Share by Region (2027–2032)

Table 21. Global Recombinant Human Coagulation VIIa Revenue by Region (US$ Million), 2021–2026

Table 22. Global Recombinant Human Coagulation VIIa Revenue Market Share by Region (2021–2026)

Table 23. Global Recombinant Human Coagulation VIIa Revenue by Region (US$ Million), 2027–2032

Table 24. Global Recombinant Human Coagulation VIIa Revenue Market Share by Region (2027–2032)

Table 25. North America Recombinant Human Coagulation VIIa Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 26. North America Recombinant Human Coagulation VIIa Sales by Country (K Units), 2021–2026

Table 27. North America Recombinant Human Coagulation VIIa Sales by Country (K Units), 2027–2032

Table 28. North America Recombinant Human Coagulation VIIa Revenue by Country (US$ Million), 2021–2026

Table 29. North America Recombinant Human Coagulation VIIa Revenue by Country (US$ Million), 2027–2032

Table 30. Europe Recombinant Human Coagulation VIIa Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 31. Europe Recombinant Human Coagulation VIIa Sales by Country (K Units), 2021–2026

Table 32. Europe Recombinant Human Coagulation VIIa Sales by Country (K Units), 2027–2032

Table 33. Europe Recombinant Human Coagulation VIIa Revenue by Country (US$ Million), 2021–2026

Table 34. Europe Recombinant Human Coagulation VIIa Revenue by Country (US$ Million), 2027–2032

Table 35. Asia Pacific Recombinant Human Coagulation VIIa Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

Table 36. Asia Pacific Recombinant Human Coagulation VIIa Sales by Region (K Units), 2021–2026

Table 37. Asia Pacific Recombinant Human Coagulation VIIa Sales by Region (K Units), 2027–2032

Table 38. Asia Pacific Recombinant Human Coagulation VIIa Revenue by Region (US$ Million), 2021–2026

Table 39. Asia Pacific Recombinant Human Coagulation VIIa Revenue by Region (US$ Million), 2027–2032

Table 40. Latin America Recombinant Human Coagulation VIIa Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 41. Latin America Recombinant Human Coagulation VIIa Sales by Country (K Units), 2021–2026

Table 42. Latin America Recombinant Human Coagulation VIIa Sales by Country (K Units), 2027–2032

Table 43. Latin America Recombinant Human Coagulation VIIa Revenue by Country (US$ Million), 2021–2026

Table 44. Latin America Recombinant Human Coagulation VIIa Revenue by Country (US$ Million), 2027–2032

Table 45. Middle East and Africa Recombinant Human Coagulation VIIa Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

Table 46. Middle East and Africa Recombinant Human Coagulation VIIa Sales by Country (K Units), 2021–2026

Table 47. Middle East and Africa Recombinant Human Coagulation VIIa Sales by Country (K Units), 2027–2032

Table 48. Middle East and Africa Recombinant Human Coagulation VIIa Revenue by Country (US$ Million), 2021–2026

Table 49. Middle East and Africa Recombinant Human Coagulation VIIa Revenue by Country (US$ Million), 2027–2032

Table 50. Global Recombinant Human Coagulation VIIa Sales (K Units) by Type (2021–2026)

Table 51. Global Recombinant Human Coagulation VIIa Sales (K Units) by Type (2027–2032)

Table 52. Global Recombinant Human Coagulation VIIa Sales Market Share by Type (2021–2026)

Table 53. Global Recombinant Human Coagulation VIIa Sales Market Share by Type (2027–2032)

Table 54. Global Recombinant Human Coagulation VIIa Revenue (US$ Million) by Type (2021–2026)

Table 55. Global Recombinant Human Coagulation VIIa Revenue (US$ Million) by Type (2027–2032)

Table 56. Global Recombinant Human Coagulation VIIa Revenue Market Share by Type (2021–2026)

Table 57. Global Recombinant Human Coagulation VIIa Revenue Market Share by Type (2027–2032)

Table 58. Global Recombinant Human Coagulation VIIa Price (US$/Unit) by Type (2021–2026)

Table 59. Global Recombinant Human Coagulation VIIa Price (US$/Unit) by Type (2027–2032)

Table 60. Global Recombinant Human Coagulation VIIa Sales (K Units) by Application (2021–2026)

Table 61. Global Recombinant Human Coagulation VIIa Sales (K Units) by Application (2027–2032)

Table 62. Global Recombinant Human Coagulation VIIa Sales Market Share by Application (2021–2026)

Table 63. Global Recombinant Human Coagulation VIIa Sales Market Share by Application (2027–2032)

Table 64. Global Recombinant Human Coagulation VIIa Revenue (US$ Million) by Application (2021–2026)

Table 65. Global Recombinant Human Coagulation VIIa Revenue (US$ Million) by Application (2027–2032)

Table 66. Global Recombinant Human Coagulation VIIa Revenue Market Share by Application (2021–2026)

Table 67. Global Recombinant Human Coagulation VIIa Revenue Market Share by Application (2027–2032)

Table 68. Global Recombinant Human Coagulation VIIa Price (US$/Unit) by Application (2021–2026)

Table 69. Global Recombinant Human Coagulation VIIa Price (US$/Unit) by Application (2027–2032)

Table 70. Novo Nordisk Company Information

Table 71. Novo Nordisk Description and Business Overview

Table 72. Novo Nordisk Recombinant Human Coagulation VIIa Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 73. Novo Nordisk Recombinant Human Coagulation VIIa Product

Table 74. Novo Nordisk Recent Developments/Updates

Table 75. LFB SA HEMA Biologics Company Information

Table 76. LFB SA HEMA Biologics Description and Business Overview

Table 77. LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 78. LFB SA HEMA Biologics Recombinant Human Coagulation VIIa Product

Table 79. LFB SA HEMA Biologics Recent Developments/Updates

Table 80. AryoGen Pharmed Company Information

Table 81. AryoGen Pharmed Description and Business Overview

Table 82. AryoGen Pharmed Recombinant Human Coagulation VIIa Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 83. AryoGen Pharmed Recombinant Human Coagulation VIIa Product

Table 84. AryoGen Pharmed Recent Developments/Updates

Table 85. GENERIUM Company Information

Table 86. GENERIUM Description and Business Overview

Table 87. GENERIUM Recombinant Human Coagulation VIIa Sales (K Units), Revenue (US$ Million), Price (US$/Unit), and Gross Margin (2021–2026)

Table 88. GENERIUM Recombinant Human Coagulation VIIa Product

Table 89. GENERIUM Recent Developments/Updates

Table 90. Key Raw Materials Lists

Table 91. Raw Materials Key Suppliers Lists

Table 92. Recombinant Human Coagulation VIIa Distributors List

Table 93. Recombinant Human Coagulation VIIa Customers List

Table 94. Recombinant Human Coagulation VIIa Market Trends

Table 95. Recombinant Human Coagulation VIIa Market Drivers

Table 96. Recombinant Human Coagulation VIIa Market Challenges

Table 97. Recombinant Human Coagulation VIIa Market Restraints

Table 98. Research Programs/Design for This Report

Table 99. Key Data Information from Secondary Sources

Table 100. Key Data Information from Primary Sources

Table 101. Authors List of This Report

List of Figures

Figure 1. Product Picture of Recombinant Human Coagulation VIIa

Figure 2. Global Recombinant Human Coagulation VIIa Market Value by Type (US$ Million), 2021–2032

Figure 3. Global Recombinant Human Coagulation VIIa Market Share by Type: 2025 & 2032

Figure 4. Prefilled Syringe Product Picture

Figure 5. Vial Product Picture

Figure 6. Global Recombinant Human Coagulation VIIa Market Value by Application (US$ Million), 2021–2032

Figure 7. Global Recombinant Human Coagulation VIIa Market Share by Application: 2025 & 2032

Figure 8. Congenital Hemophilia

Figure 9. Acquired Hemophilia

Figure 10. Others

Figure 11. Global Recombinant Human Coagulation VIIa Revenue, (US$ Million), 2021 vs 2025 vs 2032

Figure 12. Global Recombinant Human Coagulation VIIa Market Size (US$ Million), 2021–2032

Figure 13. Global Recombinant Human Coagulation VIIa Sales (K Units), 2021–2032

Figure 14. Global Recombinant Human Coagulation VIIa Average Price (US$/Unit), 2021–2032

Figure 15. Recombinant Human Coagulation VIIa Report Years Considered

Figure 16. Recombinant Human Coagulation VIIa Sales Share by Manufacturers in 2025

Figure 17. Global Recombinant Human Coagulation VIIa Revenue Share by Manufacturers in 2025

Figure 18. Top 5 and Top 10 Global Recombinant Human Coagulation VIIa Players: Market Share by Revenue in Recombinant Human Coagulation VIIa in 2025

Figure 19. Recombinant Human Coagulation VIIa Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

Figure 20. Global Recombinant Human Coagulation VIIa Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Figure 21. North America Recombinant Human Coagulation VIIa Sales Market Share by Country (2021–2032)

Figure 22. North America Recombinant Human Coagulation VIIa Revenue Market Share by Country (2021–2032)

Figure 23. United States Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 24. Canada Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 25. Europe Recombinant Human Coagulation VIIa Sales Market Share by Country (2021–2032)

Figure 26. Europe Recombinant Human Coagulation VIIa Revenue Market Share by Country (2021–2032)

Figure 27. Germany Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 28. France Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 29. U.K. Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 30. Italy Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 31. Russia Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 32. Asia Pacific Recombinant Human Coagulation VIIa Sales Market Share by Region (2021–2032)

Figure 33. Asia Pacific Recombinant Human Coagulation VIIa Revenue Market Share by Region (2021–2032)

Figure 34. China Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 35. Japan Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 36. South Korea Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 37. India Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 38. Australia Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 39. China Taiwan Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 40. Indonesia Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 41. Thailand Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 42. Malaysia Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 43. Latin America Recombinant Human Coagulation VIIa Sales Market Share by Country (2021–2032)

Figure 44. Latin America Recombinant Human Coagulation VIIa Revenue Market Share by Country (2021–2032)

Figure 45. Mexico Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 46. Brazil Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 47. Argentina Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 48. Middle East and Africa Recombinant Human Coagulation VIIa Sales Market Share by Country (2021–2032)

Figure 49. Middle East and Africa Recombinant Human Coagulation VIIa Revenue Market Share by Country (2021–2032)

Figure 50. Turkey Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 51. Saudi Arabia Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 52. UAE Recombinant Human Coagulation VIIa Revenue Growth Rate (US$ Million), 2021–2032

Figure 53. Global Sales Market Share of Recombinant Human Coagulation VIIa by Type (2021–2032)

Figure 54. Global Revenue Market Share of Recombinant Human Coagulation VIIa by Type (2021–2032)

Figure 55. Global Recombinant Human Coagulation VIIa Price (US$/Unit) by Type (2021–2032)

Figure 56. Global Sales Market Share of Recombinant Human Coagulation VIIa by Application (2021–2032)

Figure 57. Global Revenue Market Share of Recombinant Human Coagulation VIIa by Application (2021–2032)

Figure 58. Global Recombinant Human Coagulation VIIa Price (US$/Unit) by Application (2021–2032)

Figure 59. Recombinant Human Coagulation VIIa Value Chain

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Coagulation Factor VIIa Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Eptacog Alfa Recombinant Human Coagulation Factor VIIa Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Recombinant Activated Coagulation Factor VII Market Research Report 2025

Global Human Coagulation Factor VII Market Insights Forecast to 2030

Global Eptacog Alfa rFVIIa Market Research Report 2025

Global Recombinant Coagulation Factors Market Insights Forecast to 2030

Recombinant Factor VIII Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Recombinant Coagulation Factor Ⅷ for Injection Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Human Coagulation Factor Ⅷ Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Topical Recombinant Human Thrombin Market Research Report 2024

Global Recombinant Coagulation Factor IX Market Research Report 2025

Global Recombinant Coagulation Factor Concentrate Market Research Report 2024

Global Recombinant Human Coagulation Factor VIII for Injection Market Research Report 2024

Biological Hemostatic Material Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Recombinant Human Thrombin Protein Market Research Report 2024

Plasma derived Factor VIII Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Topical Recombinant Thrombin Market Research Report 2024

Global Human Coagulation Factor IX Market Research Report 2024

Coagulation Factors Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions